AI-generated · cited to primary sources · not investment advice
Max Healthcare (543220) Nov 2025 Filing Analysis
Does management do what it says?
The divestment was successfully completed in September 2025 as planned. (3 met, 1 not yet due across 4 tracked commitments)
“57% water neutrality achieved in FY25, goal of 75% by Dec’25”
Expected favorable revenue impact from CGHS price revisions once fully implemented. — target: over INR 200 crore (+1 more commitment)
“we expect a favourable impact of over INR 200 crore once fully implemented.”
See the full cited Management analysis of Max Healthcare
How durable is the business?
A significant catalyst is the CGHS tariff revision effective Oct 13, expected to provide a favorable revenue impact of over INR 200 crore with an 85% flow-through to EBITDA. (1 expanding)
“CGHS has revised the prices effective October 13th... we expect a favourable impact of over INR 200 crore once fully implemented.”
The company is further scaling its cluster approach, particularly in Noida and Lucknow, with massive land parcels (18-27 acres) allowing for potential expansion of up to 2,500 additional beds. (2 expanding)
“Similarly, in Lucknow, it is 27 acres of land. So we can go for another 2,000 - 2,500 beds there.”
See the full cited Business Model analysis of Max Healthcare
What could break the thesis?
The risk is easing as the CGHS has revised prices effective October 13th, with a projected favorable impact of over INR 200 crore once fully implemented. Management expects a 10% jump in CGHS revenue. (2 easing, 1 intensifying)
“After long last, CGHS has revised the prices effective October 13th. While some of it is yet to kick in, we expect a favourable impact of over INR 200 crore once fully implemented.”
The risk is STABLE. While Operating EBITDA margins for the Network were 26.9% in Q2 FY26 (up from 24.9% in Q1 FY26), they remain slightly below historical peaks as the company absorbs 'New Unit' costs (INR 57 Cr in overheads for Q2). (2 stable, 1 intensifying)
“Operating EBITDA 26.9%... Indirect overheads for Q2 FY26 include ₹ 57 Cr for New Units.”
See the full cited Risk analysis of Max Healthcare
AI-generated informational research only. ThesisLoop is not investment advice, a stock recommendation, or a guarantee of returns.